Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keryx, Aeterna Zentaris plummet on perifosine colorectal cancer drug failure

This article was originally published in Scrip

Executive Summary

Keryx Biopharmaceuticals tumbled as low as 67% on 2 April after it said that its novel oral anticancer Akt inhibitor, perifosine, plus Xeloda (capecitabine) missed the primary endpoint of improving overall survival versus Xeloda and placebo in the Phase III X-PECT trial to treat refractory advanced colorectal cancer.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts